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Abstract
Position statement: The Brazilian Society for Food and Nutrition (SBAN) bases the following position statement on a
critical analysis of the literature on nutritional genomics and nutrigenetic tests: (1) Nutrigenetic tests are predictive
and not diagnostic, should not replace other evaluations required to treatment, and should only be used as an
additional tool to nutritional prescription; (2) Nutritionists/registered dietitians and other health professionals must
be able to interpret the nutrigenetic tests and properly guide their patients, as well as build their professional practice on
general ethical principles and those established by regulatory authorities; (3) It is extremely important to highlight that the
misinterpretation of nutrigenetic tests can cause psychological and health problems to the patient; (4) Currently, there is
insufficient scientific evidence for the recommendation of dietary planning and nutritional supplementation based only
on nutrigenetic tests. This position statement has been externally reviewed and approved by the board of SBAN and has
not gone through the journal’s standard peer review process.
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Background
Nutritional genomics bases
The Human Genome Project (HGP), formally launched
in 1990 and finished in 2003, triggered a relevant foun-
dation for research in the health field [1]. One of the sci-
ences strongly influenced by this project was nutrition,
through the consolidation of nutritional genomics. In
the last years, a shift of paradigm in nutrition—repre-
sented by a change of focus on deficiency diseases to
those with metabolic clinical manifestations, such as
obesity, type 2 diabetes, and cardiovascular disease
(CVD)—has benefited from studies evaluating the ac-
tions of nutrients and other dietary substances at a mo-
lecular level.
Nutritional genomics is a comprehensive term that
covers nutrigenomics, nutrigenetics, and nutritional epi-
genomics, which refer to the way the environment, nu-
trients, and genes interact and how they influence
phenotype, including the disease risks. Despite the
specific boundaries of the three subdivisions, the term
Nutrigenomics is often used as a synonym for Nutri-
tional Genomics [2].
The basic concepts of nutritional genomics can be
summarized as [3]:
1. Nutrients and food components act on the human
genome, either directly or indirectly, to alter the
expression or structure of genes;
2. Under certain circumstances and in some individuals,
diet can be a serious risk factor of many diseases;
3. Some diet-regulated genes are likely to play a role in
the onset, incidence, progression, and/or severity of
noncommunicable chronic diseases (NCD);
4. The degree to which diet influences the balance
between health and disease states may depend on
the individual’s genetic makeup; and
5. Dietary intervention, based on knowledge of nutritional
requirement, nutritional status, and genotype (i.e.,
“individualized nutrition”) can be used to prevent,
mitigate, or even to cure NCD.
Nutrigenetic bases
Nutrigenetics studies the influence of genetic variability
among individuals on nutritional needs, health status,
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and the risk of developing diseases [2]. The main object-
ive of nutrigenetics is to study the effects of DNA varia-
tions, including single nucleotide polymorphisms
(SNPs), copy number variations (CNV), and insertion
and deletion (INDEL) polymorphisms in biological re-
sponses to the intake of energy, micronutrients, macro-
nutrients, and dietary bioactive compounds [4].
SNPs are the most common type of variation in the hu-
man genome (about 90% of all variations) and refer to the
replacement of only one nucleotide in a certain DNA pos-
ition (Fig. 1) [2]. When the nucleotide exchange occurs in
the coding region, it might promote a change in the struc-
ture and/or function of the translated protein. Due to the
genetic code degeneracy, when the exchange of nucleotide
does not alter the amino acid, the SNP is known as “syn-
onymous” or “silent” because it does not change the trans-
lated protein (e.g., GUC → GUA, both encode a valine).
When the change gives rise to a codon resulting in the
translation of a different amino acid, the SNP is known as
“non-synonymous” or “missense” (e.g., UUA → UCA, the
first encodes a leucine and the second, a serine). If the nu-
cleotide exchange results in a premature stop codon, the
SNP will be known as “nonsense” (e.g., UAU → UAG,
wherein the first encodes tyrosine and the second is a
stop codon).
However, a polymorphism can occur all along the
DNA molecule, including the gene promoter regions,
which can exert influence (up- or downregulation) on
gene expression. SNPs may also occur in introns and
can interfere with protein synthesis by modifying the
alternative splicing process [2, 5, 6]. Furthermore, the
biological impact also depends on the homozygous or
heterozygous condition, as the presence of only one risk
allele is often enough to determine effects of protection
or increased risk. It is important to highlight that the
risk allele may be the minor (variant) or the major
(wild), depending on the SNP studied.
An SNP may be identified in different ways. Firstly,
most SNPs are cataloged in a public database (http://
www.ncbi.nlm.nih.gov/snp/) under a registration number
(“rs”—for example rs6756629). Another way to identify
an SNP is through the nucleotide exchanged and the
DNA position (for example, rs1050450 refers to a C to T
change at position 593 of GPX1, thus 593C>T). When
an SNP occurs in the gene promoter region, it is identi-
fied with a minus sign in front of the exchange (e.g.,
−74 G>A or 74 −G/A). Moreover, as polymorphisms in
exons may alter the sequence of encoded amino acids,
this alteration can also be used to identify these SNPs.
For example, an SNP in the gene encoding the catechol-
O-methyltransferase (COMT) is cataloged under the
rs4680 and refers to a nucleotide exchange (G to A) at
position 472. This exchange results in the codification of
a methionine instead of a valine at the codon 158. Thus,
the polymorphism may be named rs4680 or G472A
(472G>A) or Val158Met. When an SNP occurs in the
promoter region or in an intron, only the nucleotide ex-
change at a certain position of the DNA will be referred
to. For example, the rs6721961 refers to the SNP −617
C>A in the promoter region of NFE2L2 (gene that codi-
fies the Nrf2, an antioxidant transcription factor). The
rs894160 is the registration number of a polymorphism
that occurs in an intron located in the perilipin gene and
can also be named as 11482 G>A.
In 2012, the results of the 1000 Genomes Project
showed that the human genome has about 38 million
SNPs possibilities. Therefore, as the human genotype
presents one variation at every 100–300 nucleotides, it
Fig. 1 Single nucleotide polymorphism: variations in nucleotides can occur all along the DNA sequence. Here, two examples of genotypes are
illustrated: a in the “common genotype” there is a codon GCT, which is transcribed into CGA in mRNA and encodes an arginine. b In the “variant
genotype,” nucleotide C was exchanged for an A. Codon GAT will be transcribed into CUA in mRNA, which encodes a leucine, promoting,
therefore, a change in the translated protein. Adapted from Camp, Trujillo [2]
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was estimated that one individual can display a subset of
up to three million SNPs. In 2015, the 1000 Genomes
project was finished, and more than 88 million variants
were characterized, of which 84.7 million were repre-
sented by SNPs and 3.6 million, by insertion/deletion
polymorphisms (INDELs) [7, 8]. It is important, how-
ever, to distinguish which SNPs have real importance in
the nutrition context. For an SNP to be classified as of
interest in nutrigenetic studies it must (I) be in genes
that respond to diet and that are activated in chronic
diseases, (II) be in genes encoding proteins considered
key in metabolism, or in other DNA regions and that
have hierarchical role in biological cascades, (III) have
important functional consequences, (IV) be highly
prevalent in the population of interest, and (V) be in
genes with associated biomarkers [9].
A classic example that can be related to nutrigenetic is
phenylketonuria (PKU), a rare autosomal recessive in-
born metabolism error, caused by mutations in the
phenylalanine hydroxylase gene (PAH). About 20 years
after PKU discovery, it was found that the patients
affected responded to dietary phenylalanine restriction
[10]. This was, therefore, the first inborn metabolism
error caused by changes in a single gene that responded
to a nutrigenetic intervention [11]. However, considering
that everyone who carries mutations in PHA will mani-
fest some degree of PKU phenotype, this condition is
considered monogenic and of high penetrance. On the
other hand, NCD, such as obesity, type 2 diabetes, CVD,
hypertension, and cancer, unlike PKU, are determined by
the interaction of multiple genes, frequent genetic varia-
tions, and the disease phenotype depends on the envir-
onmental and behavioral factors (low penetrance).
In this context, some well-established polymorphisms
importantly associated to NCDs or to related risk factors
can be highlighted, such as rs9939609 (T>A) in intron 1
of fat mass and obesity-associated gene (FTO), Ala222-
Val (rs1801133 or C677T) in the methylenetetrahydrofo-
late reductase gene (MTHFR), and rs429358 + rs7412 in
apolipoprotein E gene (APOE).
Frayling and coworkers (2007) analyzed 490,032 SNPs
of 1924 British subjects with type 2 diabetes and 2938
controls in the searching for genetic variations related to
this disease. Polymorphisms in FTO, mainly rs9939609,
were strongly associated with the presence of type 2 dia-
betes, and this association was replicated in 3757 other
patients with diabetes and 5346 controls [12].
Interestingly, risk alleles for type 2 diabetes were
strongly associated with increased body mass index
(BMI), suggesting that the relationship of polymor-
phisms with diabetes is mediated by changes in this an-
thropometric marker. The association of SNP FTO
rs9939609 with changes in BMI and with the risk of
overweight and obesity was estimated in 14,424
European adults and 10,172 children. In adults, A allele
was positively correlated with an increased risk of over-
weight and obesity in individuals of all age groups and
both sexes [12].
Afterwards, it was observed that mixed European des-
cent men carrying the genotype associated with in-
creased risk of obesity (AA) showed lower decrease of
postprandial plasma ghrelin levels and of hunger feeling,
compared to individuals carrying TT genotype [13]. In
children, it was confirmed that A allele was associated
with reduced satiety [14] and hyperphagia even after a
meal [15]. In British children, SNP FTO rs9939609 was
associated with eating behavior; those carrying the risk
allele had early obesity because of excessive food intake,
probably due to lower responsiveness to internal satiety
signals and not to reduced energy expenditure [16].
The importance of MTHFR is related to its action on
the conversion of 5,10-methylenetetrahydrofolate to
5-methyltetrahydrofolate, for subsequent donation of a
methyl group to homocysteine, so that it can be regener-
ated during the methionine/homocysteine pathway [17].
The largely studied polymorphism in MTHFR is Ala222-
Val or 677C>T (rs1801133) [18, 19], which results in the
synthesis of a more thermolabile enzyme with lower ac-
tivity (about 30% lower in heterozygous individuals and
65% lower in homozygotes for the T allele). This SNP
has been related to reduce plasma folic acid levels and
high homocysteine levels [20], which may interfere with
the global DNA methylation pattern, and increase the
CVD risk. Regarding CVD, a meta-analysis of over 70
case–control studies (n = 16,849) showed that individual
homozygotes for T allele had a 21% higher chance of de-
veloping ischemic acute myocardial infarction [21]. In
this context, T allele carriers with hyperhomocisteinemia
can benefit from higher intake of folic acid from food.
There are, however, many other genes associated with
blood homocysteine levels and DNA and histones
methylation pattern [22].
Regarding cardiovascular risk, there is great emphasis
on the role of apolipoproteins, mainly apolipoprotein E
(APOE), which plays an important role in lipid metabol-
ism, as it favors the uptake of triacylglycerol-containing
lipoprotein, participates in reverse cholesterol transport
and can influence CVD development [23]. It is estimated
that 60% of the differences observed in serum choles-
terol levels between different individuals are related to
genetic determinants, including SNPs in genes of en-
zymes, transporters, and apolipoproteins. It is important
to highlight that 14% of those differences are defined by
the SNPs APOE rs429358 and rs7412 [24, 25]. The SNPs
APOE rs429358 + rs7412 results from two variations in
exon 4 of the gene, which cause changes that are differ-
entiated by the cysteine and arginine content at codons
112 and 158, respectively. These changes result in three
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major alleles: ε2 (cysteine in both positions), ε3 (cysteine
at position 112 and arginine at 158), and ε4 (arginine at
both positions). These alleles give rise to six possibilities
of genotypes: E2/E2; E3/E3; E4/E4; E2/E3; E2/E4; and
E3/E4 [24].
Meta-analysis of 82 studies related to lipid profile of
healthy individuals and 121 studies of individuals with
CVD showed significant relationship between APOE ge-
notypes, serum levels of cholesterol in low-density lipo-
protein (LDL-C), and the risk of developing CVD. The
results showed that because ε4 allele carriers present
higher levels of serum total cholesterol and LDL-C, they
are more likely to develop CVD compared to carriers of
other alleles [25]. In a study with Brazilian individuals, it
was found that the risk of dyslipidemia was three times
greater in subjects carrying ε4 allele when compared to
ε2 carriers [26]. However, ε2 allele appears to be associ-
ated with higher plasma triacylglycerol levels [27].
Although certain genotype variations can potentially
increase the risk of diseases, diet can influence gene
expression patterns and act to reduce the risk or as
therapy, with consequent possibility of earlier positive
results.
Nutrigenomics bases
Nutrigenomics refers to the study of gene expression
modulation by nutrients and food components. In this
regard, specific nutrients or food components may in-
crease or decrease the expression of a given gene.
Gene expression regulation, in the context of nutrige-
nomics, can occur through direct and indirect mecha-
nisms. Direct mechanisms are mediated by low
molecular weight, carrier-mediated, and lipid-soluble
molecules. In contrast, indirect mechanisms are medi-
ated by larger and hydrophilic molecules that interact
on the cell surface [28].
The action of calcitriol, the vitamin D active form, rep-
resents an example of a direct nutrigenomic mechanism
in which this molecule acts as a ligand for the nuclear
receptor, the vitamin D receptor (VDR). Binding to this
nuclear receptor causes vitamin D to associate with an-
other protein, retinoid X receptor (RXR), which results
in the formation of RXR-VDR heterodimer. In turn, this
complex interacts with specific nucleotide sequences in
the DNA, called vitamin D response element (VDRE).
VDRE activation allows other transcription factors to
bind to this complex, which then modulates transcrip-
tional activity of target genes [29, 30] (Fig. 2).
Experimental studies have shown, for example, that vita-
min D modulates inflammatory responses in macro-
phages, which are cells with a large capacity for cytokine
production, particularly tumor necrosis factor (TNF)-α,
one of the most important inflammatory products re-
leased from these cells [31]. The TNF-α gene promoter
region contains a complex array of potential regulatory el-
ements. Transcriptional activation of the TNF-α gene in
macrophages has been demonstrated to be predominantly
dependent on the nuclear factor-kappa B (NF-κB), which
has four binding sites in the TNF-α promoter, and is a
major regulator of gene transcription involved in immune,
inflammatory, and stress responses. Except for mature B
cells, in which NF-κB is constitutively nuclear, in all other
cell types (including macrophages), NF-κB is maintained
in the cytoplasm via an association with the inhibitor of
kappa B (IκB), which masks NF-kB nuclear localization se-
quence [32]. When cells are activated by proinflammatory
cytokines [33], oxidants [34], or lipopolysaccharides (LPS)
[35], the IκBs are rapidly phosphorylated at two serines
within their amino-terminal regulatory domains. Phosphor-
ylation of these two sites triggers polyubiquitination and
subsequent degradation of IκBs. The loss of IκB in the cyto-
plasm and the appearance of NF-κB in the nucleus occur
simultaneously. Activated NF-κB then binds to cognate
DNA binding sites and induces gene transcription [36].
In macrophages incubated with 1,25(OH)2D3 and then
stimulated with LPS, vitamin D seems to upregulate
IκB-α levels by increasing messenger RNA (mRNA) sta-
bility and decreasing IkB-α phosphorylation. The in-
crease in IκB-α levels leads to a reduction in nuclear
translocation of NF-κB, thereby causing a decline in this
nuclear factor activity. Due to the key role of NF-κB in
pro-inflammatory response modulation, it may be sug-
gested that 1,25(OH)2D3 plays an anti-inflammatory ac-
tion in macrophages [37].
Regarding indirect mechanisms that control gene ex-
pression, nutrients or food components activate signal-
ing pathways, which in turn promote the translocation
of specific transcription factors from the cytoplasm to
the cell nucleus. Transcription factor binds to the pro-
moter region of specific genes inducing gene transcrip-
tion. Curcumin, a yellow pigment found in the rhizome
of Curcuma longa and known as turmeric, represents an
example of a food component that induces an indirect
mechanism of gene expression regulation (Fig. 3) [38].
Several studies have characterized the anti-inflammatory
actions of curcumin, combined with its antibacterial,
antiviral, antifungal, and antitumoral effects (reviewed in
ref. [39]). Curcumin modulates several in vitro molecular
targets, including the NF-kB, and the expression of
genes induced by this transcription factor, such as those
encoding cyclooxygenase (COX)-2, inducible nitric oxide
synthase (iNOS), vascular cell adhesion molecule 1
(VCAM-1), intracellular adhesion molecule 1 (ICAM-1),
TNF-α, interleukin (IL)-1, IL-6, IL-8, IL-12, and inter-
feron gamma (IFN-γ). In addition, this molecule also
inhibits the production of TNF-α induced by phorbol-
12-myristate-13-acetate (PMA) and hydrogen peroxide.
Thus, it has been suggested that the anti-inflammatory
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effects of curcumin may be attributed, in part, to its abil-
ity to trap reactive oxygen species radicals [40, 41].
In summary, nutrigenetics and nutrigenomics studies,
with distinct approaches to investigate the interaction
between diet and genes but with the common goal of
optimizing health through personalized diet, provide ef-
fective approaches to understand the complex relation-
ships among nutrients, food components, genetic
variants, and the biological system [42]. It is important
to highlight that feeding modulates several genomic
networks with different molecular targets, which makes
research in this area challenging due to the need for
high-performance molecular biology tools.
Nutritional epigenomic bases
From a simple and comprehensive way, epigenetic can
be described as reversible changes in gene expression
profiling, without alteration of the DNA sequence and
that are inherited even in the absence of the initiation
signal or event. The genome epigenetic profile is
Fig. 3 Example of an indirect mechanism mediated by curcumin. Adapted from Aggarwal [38]. NF-kB nuclear factor-kappa B, IkB kappa B inhibitor,
IKK IkB kinase, P phosphorylation, RNA P RNA polymerase, kB kB sites, VCAM-1 vascular cell adhesion molecule 1
Fig. 2 Example of a direct nutrigenomic mechanism mediated by calcitriol. Modified from Nagpal et al. [30]. VDR vitamin D receptor, RXR retinoid
X receptor, VDRE vitamin D response element
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reversible, in contrast to the static DNA sequence, and
dynamically varies from tissue to tissue and in accord-
ance with environmental exposure, featuring a high de-
gree of plasticity [43, 44]. Dietary patterns influence
cellular metabolism by modulating epigenetic events.
Accordingly, nutritional epigenomics studies the influ-
ence of the diet on epigenetic mechanisms that regulate
activity and gene expression [2, 45].
The main known epigenetic events include DNA
methylation, post transcriptional modification (acetyl-
ation, methylation, phosphorylation, etc.) in histone pro-
teins, and noncoding RNA activity (mainly microRNAs).
Similarly to genetic information, epigenetic marks are to
be transmitted to the next generation in order to be
qualified as true epigenetic information [43].
Many of those epigenetic marks, obtained at the embry-
onic stage, are closely related to the mechanisms of gen-
omic imprinting and metabolic programming and are
dynamically regulated by epigenetic remodeling through-
out life. In humans and rat, the physiology of the fetus is
influenced by the nutritional and emotional state of the
mother (especially the stress level) [46, 47]. Nutrients and
dietary bioactive compounds might modulate such events
(Fig. 4) to promote or impair health, inducing silencing or
transcriptional activation of specific genes, which ultim-
ately alter the function and cellular metabolism [48].
Some nutrients that modulate epigenetic events in-
clude (but are not limited to) amino acids such as lysine
(required for modifications on histone residues); methio-
nine (precursor of S-adenosylmethionine (SAM—methyl
donor); short chain fatty acids such as butyric acid; vita-
mins or similar essential compounds, especially vitamins
B2, B6, B12, and folic acid, choline and betaine; and min-
erals such as magnesium and zinc [49, 50]. Specific nu-
trients are needed to boost metabolic pathways that
result in methylation and both scarcity and excess of
these nutrients can directly affect the epigenome. There-
fore, a high-fat diet can influence the DNA methylation
status, for example [51]. However, the status of folic
acid, vitamin B12, methionine, choline, and betaine ap-
pear to be the most important factor for the DNA
methylation pattern, especially because these nutrients
play a critical role in methyl groups’ availability and col-
lectively regulate the one-carbon metabolism [52].
Dietary bioactive compounds are also able to modulate
the DNA methylation pattern. In cancer cell cultures,
apigenin and luteolin inhibited DNA methyltransferases
activity (DNMTs), with consequent increase in apoptosis
and decrease of cell proliferation. In turn, resveratrol
seems to reduce methylation of PTEN promoter region,
which reactivates the expression of this tumor suppres-
sor gene in breast cancer cell culture [53].
Another interesting example is calorie restriction,
which if not accompanied by nutritional deficiencies, ap-
pears to be related to longevity. This effect may be partly
mediated by modulation of epigenetic events, as it
Fig. 4 Overview of epigenetic mechanisms regulating gene expression. Dietary phytochemicals involved in DNA methylation patterns, histone
modifications, and changes in microRNA expression. Adapted from Shankar et al. [75]
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causes activation of the histone deacetylase sirtuin 1
(SIRT1). SIRT1 also induces deacetylation of histone as-
sociated to the FOXO1, FOXO3, and FOXO4 genes,
which results in modulation of cell cycle, increased de-
fenses against reactive oxygen species, and reduced
apoptosis [54].
Evidence suggests that diet can affect the disease de-
velopment risk also by modulation of miRNA expression
[55], such as in the response to high-fat diet induced
obesity in mice [56] and in the responses to adipogenic
differentiation control in offspring of rats treated with
different lipid sources [57].
Epigenetic events may be modulated according to
the environment and provide further explanation on
how diet can influence biological processes and deter-
mine phenotypes. Knowledge of such control mecha-
nisms and the establishment of epigenetic biomarkers
can help in the prescription of personalized diets for
health promotion. However, one of the most intri-
guing questions is what would be the “ideal” epige-
nomic profile for an individual, as each cell type and
even different cell types present distinct epigenetic
patterns. Also, there is evidence that epigenetic modi-
fications could be transgenerationally inherited and
early-life-acquired epigenetic marks could be reverted
throughout life via nutritional interventions [58]. But,
further studies are necessary to the full understanding
of these mechanisms.
Knowledge on nutritional genomics is being continu-
ously expanded, and there is growing interest of com-
panies in the development and commercialization of
nutrigenetic tests. Health professionals can use these
tests as an additional tool in health promotion.
Nutrigenetic tests
It is largely known that under the same nutritional inter-
vention, individuals have different biological responses.
Thus, nutritionists/registered dietitians have the oppor-
tunity of using additional tools to prescribe diets, such
as those that identify some genetic characteristics. In this
context, one of the most intriguing challenges in nutri-
tion is deciding what dietary pattern better fits individual
nutrient requirements, which are influenced by their
genotypic profile.
Genetic tests for diagnosis purposes have been used
in traditional medicine for several years to confirm a
suspected diagnosis, in the screening of inherited
diseases in individuals with familial history and in
preimplantation diagnosis. Most of these tests evalu-
ate autosomal diseases related to a single gene, in
which mutations reflect high probability (100% chance)
of disease development, such as in Huntington’s disease
[59].
Nutrigenetic tests, however, are classified as predictive
genetic tests, which means they are used to assess gen-
etic variations that increase or decrease the risk of an
event but that under no circumstances can, singly, en-
sure a diagnosis. On the other hand, these tests can be
used under the precision medicine approach or 4P
genomics—personalized, predictive, preventive, and par-
ticipatory [60]. Precision medicine is based on genomic
biomarkers targeting specific therapeutic interventions
for the individuals [61].
Nutritional genomics is an important part of precision
medicine, and nutrigenetic tests are being marketed dir-
ectly to the consumer (DTC). This approach is worrying
because, oftentimes, the knowledge necessary to prop-
erly interpret the results is insufficient. The Food and
Drug Administration describes some interesting recom-
mendations on DTC genetic tests. The main one is that
pre-symptomatic and highly predictive DTC tests avail-
able online should not be used without the involvement
of a physician or a genetic specialist. However, the FDA
and a group of experts concluded that nutrigenetic tests
have a low-risk level if analytically and clinically vali-
dated [62].
In the UK, the first nutrigenetic test was launched in
2001, but scientists and clinicians were skeptical that re-
searches were ready to be translated into clinical trials
[63]. In Brazil, nutrigenetic tests emerged from 2011 and
currently there is an increasing number of companies of-
fering genotyping services with different approaches and
diverse polymorphisms in the tests.
Therefore, with the increased opportunity of carrying
out predictive nutrigenetic tests, it is crucial that nutri-
tionists/registered dietitians and other health profes-
sionals are able to understand, interpret, and use these
tests properly. It should be noted that the nutritional
prescription based on nutrigenetic tests must focus on
health and life quality promotion [64].
Nutrigenetic tests focus on the analysis of genetic
variations, especially SNPs, that can predict the indi-
vidual nutritional needs, in order to guide interven-
tions to reduce the risk of chronic diseases. In the
last years, the expression “one size does not fit all”
has been applied in studies about genes—diet interac-
tions. Thus, nutrigenetics can be a tool to achieve the
optimum amounts of nutrients in an individual and
personalized approach [65].
Nevertheless, it is necessary to point out that although
the first draft of the human genome have been an-
nounced since 2001, the function of all genes and the
possible relationships between genes and diseases are
still unknown. Therefore, it should be emphasized that
nutrigenetic tests, solely, are not sufficient for diet
customization and not even for prescribing supplements.
In this context, it is noteworthy that unlike monogenic
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diseases (e.g., phenylketonuria), nutrigenetic tests for
complex polygenic conditions (e.g., obesity, cancer, type
2 diabetes, intolerances, dyslipidemia, hypertension, etc.)
are only predictive of the associated risk.
Nutrigenetic tests are based on the principle that indi-
viduals respond differently to acute or repeated exposure
to a particular nutrient, a dietary bioactive compound,
or to a combination of them. Usually, these tests analyze
polymorphisms in genes primarily involved with obesity
and associated comorbidities, metabolism and transport
of nutrients, pro-inflammatory response, and detoxifica-
tion enzymes and antioxidants. Therefore, according to
the genetic variations of an individual and considering
other aspects, such as family history, clinical evaluation,
and biochemical tests, personalized nutritional counsel-
ing can be prepared and include nutritional and lifestyle
advice to achieve specific goals, such as weight loss or
blood glucose and cholesterol control.
It is also important to highlight that all the possible as-
sociations between SNPs and other factors that contrib-
ute to the emergence of diseases are not completely
known, which implies that the absolute risks from such
associations are still low. In addition, in polygenic condi-
tions, beyond the influence of several SNPs, it is ex-
tremely important to consider the role of environmental
factors, such as the level of physical activity, emotional
stress, smoking, alcohol intake, and dietary habits, which
can modify gene expression patterns (especially through
epigenetic mechanisms) and the risk of developing dis-
eases. In this context, epigenome-wide association stud-
ies (EWAS) help to identify epigenetic biomarkers of
metabolic health, which will be useful for monitoring
the individual who receives a nutritional prescription
[66]. Another point to be considered is the interpret-
ation of nutrigenetic tests results, as it depends on many
factors including how many and which SNPs are evalu-
ated, which studies supported the interpretation, envir-
onmental factors, and the interaction with other
unassessed genetic factors.
One example of SNP evaluated in nutrigenetic test is
rs4988235, lactose intolerance-associated. Lactase is
encoded by the LCT gene, located in chromosome region
2q.21 and highly expressed in newborns. After the lacta-
tion period, LCT expression decreases and adults lose, at
least in part, the ability to metabolize lactose. However,
some individuals retain this ability, which is known as
persistence of lactase, a dominant condition that arose
in northern Europe from mutations in MCM6 gene, ad-
jacent to the LCT gene, in a region acting as a promoter
of lactase expression. In Europeans, the polymorphism
associated with lactase persistence is MCM6 −13910
C>T (rs4988235), wherein the presence of T allele deter-
mines the persistence of the enzyme. However, in
African Americans and Asians, the frequency of this
polymorphism is very low and cannot be related to lac-
tase persistence, which highlights ethnic differences in-
volved in the determination of specific phenotypes [67].
Another example of SNP evaluated in nutrigenetic
tests is rs762551 (−164 A>C) in CYP1A2. This gene en-
codes CYP1A2, a xenobiotic metabolizing enzyme re-
sponsible for ~13% of hepatic cytochrome P450 activity
[68] and, among other compounds, for caffeine (1,3,7-
trimethylxanthine) metabolism [69]. The presence of C
allele (also referred to as CYP1A2 *1F) associates with
reduced enzyme metabolizing capacity compared to the
presence of two allele A (also designed as CYP1A2 *1A/
*1A). Therefore, individuals carrying two major alleles
(AA) are classified as “fast” metabolizers, while those
carrying minor alleles (one or two) are “slow” meta-
bolizers of caffeine. The main clinical relevance of be-
ing fast or slow metabolizer of caffeine is related to
the risk of cardiovascular disease. In this context,
slow metabolizers of caffeine showed higher risk of
acute myocardial infarction with increased coffee con-
sumption (>500 mL/day), which was not observed in
fast metabolizers [70].
In a clinical practice experience, Arkadianos and col-
leagues (2007) [71] evaluated 50 patients who underwent
a nutrigenetic test and a group of 43 patients (matched
for age, sex, and frequency of visits) who received a
standard diet for weight loss. Custom guidelines were
directed according to the genetic profile (24 SNPs) of
each patient. In the first trimester, patients of both
groups showed similar weight reduction. However,
after 1 year of intervention, patients who received nu-
tritional prescription according to the genetic profile
continued to lose weight, while those who received
the traditional prescription regained weight. Moreover,
only the group who received the guidelines custom-
ized by genotype showed a significant improvement
in fasting glucose levels.
Another study aimed to compare the results of stand-
ard nutritional versus genotype customized guidance.
The diet was prescribed according to the results of seven
SNPs [APOA2 (rs5082), ADIPOQ (rs17300539), FTO
(rs9939609), KCTD10 (rs10850219), LIPC (rs1800588),
MMAB (rs2241201), and PPARG (rs1801282)]. Nutri-
tional counseling was standardized between groups, and
the nutrigenetic test group followed a diet with different
carbohydrates, lipid, and protein distribution (balanced,
low-carbohydrate, low-fat, or Mediterranean diets).
There was no significant difference between the groups
in the percentage of participants who showed a reduc-
tion of 5% of their body weight after 8 or 24 weeks of
intervention. Both groups had difficulty to follow the di-
ets; however, adherence correlated with weight loss in
the nutrigenetic test group, which did not occur in the
control group [72].
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Complex diseases such as type 2 diabetes, cancer, and
cardiovascular disease are the result of interaction be-
tween environmental and genetic factors, and genetic vari-
ations are only predictors of risk. Because of the large
number of possible interactions, the association between
genes, diseases, and the environment is not yet fully
understood, which excludes the possibility of diagnosis
through nutrigenetic tests. Thus, nutritional care based on
nutrigenetic tests must include all stages of the conven-
tional nutritional care, with the investigation of family his-
tory, biochemical markers, nutritional and anthropometric
aspects, risk factors of chronic diseases, and other features
considered necessary by the health professional.
The decision to hold or not a nutrigenetic test should
be taken by the patient. The health professional has
the obligation of informing all the risks, benefits and
limitations, and resolve doubts. The interpretation of
the results should be careful, and the transmission of
results to patients should be performed by trained
professionals—preferably by a genetic specialist—who
have sufficient knowledge of nutritional genomics, as such
results can provide information about the risk of develop-
ing disease that has no cure, such as Alzheimer’s disease.
These results must be explained carefully to avoid
alarming patients incorrectly. In this context, it is im-
portant to note that studies have revealed large gaps
in knowledge and skills of health professionals, including
nutritionists/registered dietitians, in developed countries
such as Canada and the UK [73, 74].
Moreover, ethical issues must be widely discussed and
considered. Aspects such as confidentiality of data; pre-
diction of future health events; possible prejudice or dis-
crimination arising from the results in any magnitude,
including health insurances and employers; the popula-
tion access to nutrigenetic tests; as well as aspects re-
lated to analytical quality of companies that provide
these tests should be deeply evaluated. From a public
health viewpoint, relevant social concerns relate to the
possibility that genetic tests may cause social disparities.
In addition, the need for specific legislations and inspec-
tion is paramount.
In short, nutrigenetic tests can help in the individual-
ized nutrition prescription and should be used to com-
plement the nutritional care and not replace any
traditional assessment tool. Individual response to a nu-
trient intake is the result of interaction between metab-
olism; environment, social, spiritual, emotional and
genetic aspects; and the microbiome. Therefore, nutrige-
netic tests alone are not sufficient for diet customization,
not even for prescribing supplements. However, there is
overwhelming evidence for the use of certain genetic
variations as a basis for nutritional prescription after a
careful nutritional, anthropometric, clinical, and bio-
chemical assessment.
The practical application of nutrigenetic tests also de-
pends on the expansion of knowledge on the interac-
tions between genes, nutrition, health, and disease and
more specific information about the actual individual
nutritional needs. In addition, more accurate informa-
tion about the bioavailability of nutrients and dietary
bioactive compounds are necessary, which will result in
the reassessment of nutritional recommendations
Research on nutritional genomics has the potential to
answer some important questions, for example, whether
healthy phenotypes can be obtained from the adoption
of some dietary patterns and if this outcome depends on
the isolate intake of a specific nutrient or bioactive food
component. In this context, it is very important to evalu-
ate which are the specificities of nutrients and bioactive
food components on different life stages.
Despite the obstacles faced by scientists, the nutri-
tional genomics field undoubtedly continues to evolve
and will impact the recommendation of nutrients and
health promotion. SBAN, concerned with questions re-
lated to the use of nutrigenetic tests in the clinical prac-
tice of nutritionists and other health professionals, has
put efforts in the elaboration of this technical position
so that correct and updated information can be widely
disseminated.
Summary of recommendations
 Nutrigenetic tests are predictive and not diagnostic,
should not replace other evaluations required to
treatment, and should only be used as an additional
tool to nutritional prescription;
 Nutritionists/registered dietitians and other health
professionals must be able to interpret the nutrigenetic
tests and properly guide their patients, as well as build
their professional practice on general ethical principles,
and those established by regulatory authorities;
 It is extremely important to highlight that the
misinterpretation of nutrigenetic tests can cause
psychological and health problems to the patient;
 Currently, there is insufficient scientific evidence for
the recommendation of dietary planning and nutritional
supplementation based only on nutrigenetic tests.
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